Review of Oral Anticoagulants for Atrial Fibrillation
Author Information
Author(s): Raul Altman, Hector O Vidal
Primary Institution: Centro de Trombosis de Buenos Aires
Hypothesis
Can new oral anticoagulants effectively replace warfarin for stroke prevention in patients with atrial fibrillation?
Conclusion
New oral anticoagulants show promise but cannot yet replace warfarin until further studies confirm their safety and effectiveness.
Supporting Evidence
- Warfarin has been shown to reduce the risk of ischemic stroke significantly compared to aspirin.
- New oral anticoagulants like dabigatran and rivaroxaban are being studied for their effectiveness.
- Patients with atrial fibrillation have a higher risk of stroke, necessitating effective anticoagulation.
Takeaway
Doctors are looking for new medicines to prevent strokes in patients with heart problems, but the old medicine, warfarin, is still the best option for now.
Methodology
Review of existing studies comparing warfarin with new oral anticoagulants.
Potential Biases
Potential bias in study selection and reporting of outcomes.
Limitations
The review relies on existing studies, which may not fully represent real-world patient demographics.
Participant Demographics
Patients with atrial fibrillation, including those at varying risk levels.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website